Literature DB >> 25835554

Heme oxygenase-1 gene promoter polymorphism and the risk of pediatric nonalcoholic fatty liver disease.

P-F Chang1, Y-C Lin1, K Liu2, S-J Yeh1, Y-H Ni3.   

Abstract

BACKGROUND AND OBJECTIVES: Oxidative stress and the insulin-resistant state are thought to be key components in the pathogenesis of pediatric nonalcoholic fatty liver disease (NAFLD). Heme oxygenase (HO) is important in the defense against oxidative stress. This study aimed to assess the association of HO-1 gene promoter polymorphism and insulin resistance with NAFLD among obese children.
METHODS: A total of 101 obese children aged 6-17 years were recruited. Anthropometric, serum biochemical variables and biomarkers for glucose and insulin metabolism were measured. We screened the allelic frequencies of (GT)n repeats in the HO-1 gene promoter among these obese children. NAFLD was determined through liver ultrasonography. Because the distribution of numbers of (GT)n repeats was bimodal, we divided the alleles into two classes: class S included shorter (27) repeats, and class L included longer (⩾27) repeats. We assessed the effects of the length of (GT)n repeats in HO-1 gene promoter on pediatric NAFLD.
RESULTS: Of the 101 obese subjects, 27 (26.7%) had NAFLD. The alanine aminotransferase level was higher in patients carrying L alleles (L/L and L/S) than patients with S alleles (S/S) (46.2±49.3 IU|(-1) versus 30.2±20.1 IU|(-1); P=0.027). The significant risk factors for pediatric NAFLD were patients carrying L alleles (L/L and L/S) (odds ratio (OR)=18.84; 95% confidence interval (CI): 1.45-245.22; P=0.025), homeostasis model assessment of insulin resistance (OR=1.40; 95% CI: 1.07-1.83; P=0.014) and age (OR=1.24; 95% CI: 1.03-1.50; P=0.025).
CONCLUSION: In this hospital-based study, the obese children with longer GT repeats in the HO-1 gene promoter and insulin resistance were susceptible to NAFLD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25835554     DOI: 10.1038/ijo.2015.46

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  38 in total

1.  Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis.

Authors:  Ruben Hernaez; Mariana Lazo; Susanne Bonekamp; Ihab Kamel; Frederick L Brancati; Eliseo Guallar; Jeanne M Clark
Journal:  Hepatology       Date:  2011-09-02       Impact factor: 17.425

Review 2.  Comparison of overweight and obesity prevalence in school-aged youth from 34 countries and their relationships with physical activity and dietary patterns.

Authors:  I Janssen; P T Katzmarzyk; W F Boyce; C Vereecken; C Mulvihill; C Roberts; C Currie; W Pickett
Journal:  Obes Rev       Date:  2005-05       Impact factor: 9.213

Review 3.  Review: The role of insulin resistance in nonalcoholic fatty liver disease.

Authors:  Kristina M Utzschneider; Steven E Kahn
Journal:  J Clin Endocrinol Metab       Date:  2006-09-12       Impact factor: 5.958

Review 4.  Carbon monoxide and bilirubin: potential therapies for pulmonary/vascular injury and disease.

Authors:  Stefan W Ryter; Danielle Morse; Augustine M K Choi
Journal:  Am J Respir Cell Mol Biol       Date:  2006-09-15       Impact factor: 6.914

5.  d(TG)n.d(CA)n sequences upstream of the rat prolactin gene form Z-DNA and inhibit gene transcription.

Authors:  L H Naylor; E M Clark
Journal:  Nucleic Acids Res       Date:  1990-03-25       Impact factor: 16.971

Review 6.  Heme oxygenase-1 (HO-1), a protective gene that prevents chronic graft dysfunction.

Authors:  Niels Olsen Saraiva Camara; Miguel Parreira Soares
Journal:  Free Radic Biol Med       Date:  2005-02-15       Impact factor: 7.376

7.  Protection of transplant-induced renal ischemia-reperfusion injury with carbon monoxide.

Authors:  Joao Seda Neto; Atsunori Nakao; Kei Kimizuka; Anna Jeanine Romanosky; Donna B Stolz; Takashi Uchiyama; Michael A Nalesnik; Leo E Otterbein; Noriko Murase
Journal:  Am J Physiol Renal Physiol       Date:  2004-08-03

8.  Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis.

Authors:  Andrew J Lickteig; Craig D Fisher; Lisa M Augustine; Nathan J Cherrington
Journal:  J Biochem Mol Toxicol       Date:  2007       Impact factor: 3.642

9.  Heme oxygenase-1 protects against steatohepatitis in both cultured hepatocytes and mice.

Authors:  Jun Yu; Eagle S H Chu; Ruizhi Wang; Shiyan Wang; Chung W Wu; Vincent W S Wong; Henry L Y Chan; Geofferey C Farrell; Joseph J Y Sung
Journal:  Gastroenterology       Date:  2009-10-07       Impact factor: 22.682

10.  Increased HO-1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21.

Authors:  Terry D Hinds; Komal Sodhi; Charles Meadows; Larisa Fedorova; Nitin Puri; Dong Hyun Kim; Stephen J Peterson; Joseph Shapiro; Nader G Abraham; Attallah Kappas
Journal:  Obesity (Silver Spring)       Date:  2013-12-02       Impact factor: 5.002

View more
  11 in total

Review 1.  Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review.

Authors:  Tyler J Severson; Siddesh Besur; Herbert L Bonkovsky
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

Review 2.  The Genetics of Pediatric Nonalcoholic Fatty Liver Disease.

Authors:  Nidhi P Goyal; Jeffrey B Schwimmer
Journal:  Clin Liver Dis       Date:  2017-10-05       Impact factor: 6.126

3.  Factors early in life associated with hepatic steatosis.

Authors:  Sabrina Xin Zi Quek; Eunice Xiang-Xuan Tan; Yi Ping Ren; Mark Muthiah; Evelyn Xiu Ling Loo; Elizabeth Huiwen Tham; Kewin Tien Ho Siah
Journal:  World J Hepatol       Date:  2022-06-27

Review 4.  Mitochondrial role in the neonatal predisposition to developing nonalcoholic fatty liver disease.

Authors:  Peter R Baker; Jacob E Friedman
Journal:  J Clin Invest       Date:  2018-08-31       Impact factor: 14.808

5.  Sex-, Age-, and Race/Ethnicity-Dependent Variations in Drug-Processing and NRF2-Regulated Genes in Human Livers.

Authors:  Jie Liu; Julia Yue Cui; Yuan-Fu Lu; J Christopher Corton; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2020-11-08       Impact factor: 3.922

Review 6.  Two Faces of Heme Catabolic Pathway in Newborns: A Potential Role of Bilirubin and Carbon Monoxide in Neonatal Inflammatory Diseases.

Authors:  Wiktoria Osiak; Sławomir Wątroba; Lucyna Kapka-Skrzypczak; Jacek Kurzepa
Journal:  Oxid Med Cell Longev       Date:  2020-08-18       Impact factor: 6.543

Review 7.  New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease.

Authors:  Yu-Cheng Lin; Chi-Chien Wu; Yen-Hsuan Ni
Journal:  Front Pediatr       Date:  2020-12-09       Impact factor: 3.418

Review 8.  Modeling Non-Alcoholic Fatty Liver Disease (NAFLD) Using "Good-Fit" Genome-Editing Tools.

Authors:  Uijin Kim; Nahyun Kim; Ha Youn Shin
Journal:  Cells       Date:  2020-12-01       Impact factor: 6.600

9.  The effect of endurance training on non-alcoholic fatty liver disease in mice.

Authors:  Luma Melo; Merve Bilici; Amit Hagar; James E Klaunig
Journal:  Physiol Rep       Date:  2021-08

10.  Association of Serum Bilirubin and Functional Variants of Heme Oxygenase 1 and Bilirubin UDP-Glucuronosyl Transferase Genes in Czech Adult Patients with Non-Alcoholic Fatty Liver Disease.

Authors:  Jaromír Petrtýl; Karel Dvořák; Jan Stříteský; Martin Leníček; Alena Jirásková; Václav Šmíd; Martin Haluzík; Radan Brůha; Libor Vítek
Journal:  Antioxidants (Basel)       Date:  2021-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.